---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000014"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:51:01.237254+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio amends $505M convertible note to allow partial conversion at any time

## Summary
- Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.
- Previously, partial conversion was not permitted under the December 2024 note; no other terms changed.
- Holder Nant Capital is an affiliate of Executive Chairman Dr. Patrick Soon-Shiong, making this a related-party transaction.

## SEC filing metadata
- accession: 0001326110-26-000014
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/ibrx-20260123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000014
- JSON: https://secwatch.observer/filing/0001326110-26-000014.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000014.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: Nant Capital, LLC
  - Effective: 2026-01-23
  source text: On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.